Results for tag: "Zollinger Ellison Syndrome Drug"

The Zollinger Ellison Syndrome (ZES) Drug market is a subset of the Gastrointestinal Drugs market. ZES is a rare disorder characterized by the presence of gastrin-secreting tumors in the pancreas and duodenum. These tumors cause the body to produce too much gastrin, leading to an increase in stomach acid production and the development of peptic ulcers. Treatment for ZES typically involves the use of proton pump inhibitors (PPIs) to reduce stomach acid production and H2 receptor antagonists to reduce gastric acid secretion. In addition, surgery may be necessary to remove the tumors. The ZES Drug market is highly competitive, with a number of major pharmaceutical companies offering products to treat the disorder. These include AstraZeneca, Pfizer, Takeda, Novartis, and Merck. Other companies, such as AbbVie, Boehringer Ingelheim, and Daiichi Sankyo, also offer products for the treatment of ZES. Show Less Read more